Altimmune

Yahoo Finance • 19 hours ago

ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story

Yahoo Finance • 3 days ago

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 3 days ago

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune”... Full story

Yahoo Finance • 3 days ago

Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between Aug... Full story

Yahoo Finance • 4 days ago

ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 6th Deadline in the Altimmune Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August... Full story

Yahoo Finance • 4 days ago

ALT DEADLINE: ROSEN, LEADING INVESTOR RIGHTS ATTORNEYS, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story

Yahoo Finance • 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton a... Full story

Yahoo Finance • 5 days ago

Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 6 days ago

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 – ALT

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 7 days ago

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story

Yahoo Finance • 7 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Al... Full story

Yahoo Finance • 9 days ago

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit – ALT

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 9 days ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. (NASDAQ:... Full story

Yahoo Finance • 10 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story

Yahoo Finance • 10 days ago

ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to cont... Full story

Yahoo Finance • 11 days ago

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between Aug... Full story

Yahoo Finance • 12 days ago

Shareholders that lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 13 days ago

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story

Yahoo Finance • 13 days ago

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to cont... Full story

Yahoo Finance • 13 days ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the... Full story